HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).

被引：0
|
作者：
Mateos, Maria-Victoria
Oriol, Albert
Larocca, Alessandra
Blade, Joan
Cavo, Michele
Rodriguez Otero, Paula
Leleu, Xavier
Hiemenz, John W.
Hassoun, Hani
Touzeau, Cyrille
Alegre, Adrian
Paner, Agne
Maisel, Christopher
Mazumder, Amitabha
Raptis, Anastasios
Harmenberg, Johan
Zavisic, Stojan
Thuresson, Sara
Ohman, Oskar
Richardson, Paul G.
机构：
[1] Univ Hosp Salamanca, Canc Res Ctr IBMCC USAL CSIC, IBSAL, Salamanca, Spain
[2] Hosp Badalona Germans Trias & Pujol, Inst Invest Leucemia Josep Carreras, Badalona, Spain
[3] Hosp Badalona Germans Trias & Pujol, Inst Catela Oncol, Badalona, Spain
[4] AOU Citta Salute & Sci Torino SC, Ematol u, Torin, Italy
[5] Hosp Clin Barcelona, Serv Oncohematol, Barcelona, Spain
[6] St Orsola Marcello Malpighi Hosp, Bologna, Italy
[7] Clin Univ Navarra Pamploma, Navarra, Spain
[8] CHU Poitiers, Poitiers, France
[9] Univ Florida, Hlth Canc Ctr, Gainesville, FL USA
[10] Mem Sloan Kettering Canc, Myeloma Serv, Dept Med, New York, NY USA
[11] Ctr Hosp Univ, Nantes, France
[12] Hosp Univ La Princesa, Madrid, Spain
[13] Assoc Med Onc, Bolingbrook, IL USA
[14] Baylor Scott & White Charles A Sammons Canc Ctr, Dallas, TX USA
[15] Oncol Inst Hope & Innovat, Glendale, CA USA
[16] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[17] Oncopeptides AB, Stockholm, Sweden
[18] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20570
引用
收藏
页数：2
相关论文
共 50 条
  • [21] OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed/Refractory Multiple Myeloma (RRMM) - Impact of Prior Treatments Analysis
    Dimopoulos, Meletios-Athanasios
    Schjesvold, Fredrik H.
    Mateos, Maria-Victoria
    Robak, Pawel J.
    Hajek, Roman
    Richardson, Paul G.
    Lindberg, Jakob
    Thuresson, Marcus
    Larsson, Kajsa
    Sonneveld, Pieter
    BLOOD, 2021, 138
  • [22] Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.
    Rodriguez-Otero, Paula
    Mateos, Maria-Victoria
    Oriol, Albert
    Larocca, Alessandra
    Blade, Joan
    Cavo, Michele
    Leleu, Xavier
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Alegre, Adrian
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Thuresson, Marcus
    Harmenberg, Johan
    Harlin, Olof
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Subgroup Analysis By Prior Alkylator Exposed/Refractory Status
    Sonneveld, Pieter
    Mateos, Maria-Victoria
    Robak, Pawel J.
    Schjesvold, Fredrik H.
    Hajek, Roman
    Richardson, Paul G.
    Harmenberg, Johan
    Thuresson, Marcus
    Byrne, Catriona
    Dimopoulos, Meletios-Athanasios
    BLOOD, 2021, 138
  • [24] HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional Agents
    Creixenti, Joan Blade
    Mateos, Maria-Victoria
    Oriol, Albert
    Larocca, Alessandra
    Cavo, Michele
    Rodriguez-Otero, Paula
    Leleu, Xavier
    Norkin, Maxim
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Amor, Adrian Alegre
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Puig, Noemi
    Zavisic, Stojan
    Thuresson, Marcus
    Harmenberg, Johan
    Richardson, Paul G.
    BLOOD, 2020, 136
  • [25] LIGHTHOUSE (OP-108): A phase 3 study of melflufen in combination with dexamethasone (dex) and daratumumab (dara) versus dara in relapsed/refractory multiple myeloma (RRMM) patients (pts).
    Mateos, Maria-Victoria
    Pour, Ludek
    Ocio, Enrique M.
    Sonneveld, Pieter
    Blixt, Catarina Jansson
    Larsson, Kajsa
    Palmer, Linda
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Long-Term Outcomes and Safety of Continuous Lenalidomide Plus Dexamethasone (Len plus Dex) Treatment in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM)
    Dimopoulos, Meletios Athanasios
    Hussein, Mohamad
    Swern, Arlene S.
    Weber, Donna M.
    BLOOD, 2011, 118 (21) : 1263 - 1263
  • [27] ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM)-Optimal dose, updated efficacy and safety results.
    Hajek, Roman
    Pour, Ludek
    Granell, Miquel
    Maisnar, Vladimir
    Richardson, Paul G.
    Norin, Stefan
    Sydvander, Malin
    Obermueller, Jakob
    Ocio, Enrique M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies
    Rodriguez-Otero, Paula
    Mateos, Maria-Victoria
    Oriol, Albert
    Larocca, Alessandra
    Blade, Joan
    Cavo, Michele
    Leleu, Xavier
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Alegre, Adrian
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Thuresson, Marcus
    Harmenberg, Johan
    Harlin, Olof
    Richardson, Paul G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S426 - S427
  • [29] Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab
    Mateos, Maria-Victoria
    Oriol, Albert
    Larocca, Alessandra
    Otero, Paula Rodriguez
    Blade, Joan
    Cavo, Michele
    Hassoun, Hani
    Leleu, Xavier
    Amor, Adrian Alegre
    Maisel, Christopher
    Paner, Agne
    Harmenberg, Johan
    Byrne, Catriona
    Thuresson, Sara
    Zubair, Hanan
    Richardson, Paul G.
    BLOOD, 2019, 134
  • [30] Anchor (OP-104): melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma (RRMM) - final efficacy and safety results
    Ocio, Enrique
    Efebera, Yvonne
    Hajek, Roman
    Straub, Jan
    Maisnar, Vladimir
    Eveillard, Jean-Richard
    Karlin, Lionel
    Mateos, Maria-Victoria
    Oriol, Albert
    Ribrag, Vincent
    Richardson, Paul
    Norin, Stefan
    Obermuller, Jakob
    Bakker, Nicolaas
    Pour, Ludek
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S204 - S204
12345